Literature DB >> 26912922

Ivadradine.

Dennis J Cada1, Ross Bindler2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2015 monograph topics are sacubitril/valsartan, daclatasvir, sonidegib, alirocumab, and sodium zirconium cyclosilicate. The Safety MUE is on sacubitril/valsartan.

Entities:  

Year:  2015        PMID: 26912922      PMCID: PMC4750831          DOI: 10.1310/hpj5009-806

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  40 in total

1.  Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.

Authors:  Luigi Tavazzi; Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Mitja Lainscak; Ian Ford
Journal:  Eur J Heart Fail       Date:  2013-06-26       Impact factor: 15.534

2.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Authors:  Jean-Claude Tardif; Ian Ford; Michal Tendera; Martial G Bourassa; Kim Fox
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

3.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey Borer; Michele Robertson; Luigi Tavazzi; Ian Ford
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

4.  Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.

Authors:  Yuksel Cavusoglu; Ugur Mert; Aydin Nadir; Fezan Mutlu; Bektas Morrad; Taner Ulus
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2015-09       Impact factor: 2.160

5.  Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.

Authors:  Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Michele Robertson; Athanasios J Manolis; Luigi Tavazzi; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2014-06-24       Impact factor: 15.534

6.  Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2009-11-05       Impact factor: 15.534

7.  Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure.

Authors:  Jan-Christian Reil; Michele Robertson; Ian Ford; Jeffrey Borer; Michel Komajda; Karl Swedberg; Luigi Tavazzi; Michael Böhm
Journal:  Eur J Heart Fail       Date:  2013-05-21       Impact factor: 15.534

8.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

9.  Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.

Authors:  Jeffrey S Borer; Jean-Claude Tardif
Journal:  Am J Cardiol       Date:  2009-11-10       Impact factor: 2.778

10.  Nemaline myopathy and heart failure: role of ivabradine; a case report.

Authors:  Filippo M Sarullo; Giuseppe Vitale; Antonino Di Franco; Silvia Sarullo; Ylenia Salerno; Laura Vassallo; Emanuela Petrona Baviera; Stefania Marazia; Giorgio Mandalà; Gaetano A Lanza
Journal:  BMC Cardiovasc Disord       Date:  2015-01-19       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.